BRIEF-Kestra Medical Technologies Inc Q3 EPS USD -0.61

Reuters

03/18

BRIEF-<a href="https://laohu8.com/S/KMTS">Kestra Medical Technologies Inc</a> Q3 EPS USD -0.61

Mar 17 (Reuters) - Kestra Medical Technologies Inc Q3 adjusted EBITDA USD -21.191 million vs. IBES estimate USD -20.7 million.

Q3 income from operations USD -34.765 million
Q3 revenue USD 24.552 million vs. IBES estimate USD 22.9 million
Q3 gross profit USD 12.906 million
outlook FY revenue USD 93 million vs. IBES estimate USD 90.9 million
outlook FY revenue growth 55%

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2620408388"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620408388\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620408388?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620408388","market":"fut","top_or_hot":-1,"title":"BRIEF-Kestra Medical Technologies Inc Q3 EPS USD -0.61","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-<a href=\"https://laohu8.com/S/KMTS\">Kestra Medical Technologies Inc</a> Q3 EPS USD -0.61</title>\n</head>\n<body>\n<p>Mar 17 (Reuters) - Kestra Medical Technologies Inc Q3 adjusted EBITDA USD -21.191 million vs. IBES estimate USD -20.7 million.</p>\n<ul>\n<li>Q3 income from operations USD -34.765 million</li>\n<li>Q3 revenue USD 24.552 million vs. IBES estimate USD 22.9 million</li>\n<li>Q3 gross profit USD 12.906 million</li>\n<li>outlook FY revenue USD 93 million vs. IBES estimate USD 90.9 million</li>\n<li>outlook FY revenue growth 55%</li>\n</ul>\n</body>\n</html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kestra Medical Technologies Inc Q3 EPS USD -0.61</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kestra Medical Technologies Inc Q3 EPS USD -0.61\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<meta/>\n<title>BRIEF-<a href=\"https://laohu8.com/S/KMTS\">Kestra Medical Technologies Inc</a> Q3 EPS USD -0.61</title>\n</head>\n<body>\n<p>Mar 17 (Reuters) - Kestra Medical Technologies Inc Q3 adjusted EBITDA USD -21.191 million vs. IBES estimate USD -20.7 million.</p>\n<ul>\n<li>Q3 income from operations USD -34.765 million</li>\n<li>Q3 revenue USD 24.552 million vs. IBES estimate USD 22.9 million</li>\n<li>Q3 gross profit USD 12.906 million</li>\n<li>outlook FY revenue USD 93 million vs. IBES estimate USD 90.9 million</li>\n<li>outlook FY revenue growth 55%</li>\n</ul>\n</body>\n</html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nPLXD86622:1","article_id":"2620408388","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620408388","pubTimestamp":1773777705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mar 17  - Kestra Medical Technologies Inc Q3 adjusted EBITDA USD -21.191 million vs. IBES estimate USD -20.7 million.outlook FY revenue USD 93 million vs. IBES estimate USD 90.9 million","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","KMTS":"Kestra Medical Technologies Inc"},"translate_title":"简介-Kestra Medical Technologies Inc第三季度EPS USD-0.61","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMTS":0.9},"content_text":"BRIEF-Kestra Medical Technologies Inc Q3 EPS USD -0.61\n\n\nMar 17 (Reuters) - Kestra Medical Technologies Inc Q3 adjusted EBITDA USD -21.191 million vs. IBES estimate USD -20.7 million.\n\nQ3 income from operations USD -34.765 million\nQ3 revenue USD 24.552 million vs. IBES estimate USD 22.9 million\nQ3 gross profit USD 12.906 million\noutlook FY revenue USD 93 million vs. IBES estimate USD 90.9 million\noutlook FY revenue growth 55%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}